Keywords: ایدارویزوماب; Cardioembolic stroke; dabigatran; idarucizumab; nonvalvular atrial fibrillation; recombinant tissue plasminogen activator;
مقالات ISI ایدارویزوماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ایدارویزوماب; Idarucizumab; dabigatran; anticoagulation reversal; bleeding; surgery; thrombolysis;
Keywords: ایدارویزوماب; Idarucizumab; aripazine; andexanet alfa; thromboprophylaxis; direct oral anticoagulants; DOAC; reversal agents; pharmacology of DOACs;
Keywords: ایدارویزوماب; Anticoagulant reversal; Novel oral anticoagulants; Warfarin; Heparin; Prothrombin complex concentrate; Idarucizumab;
Keywords: ایدارویزوماب; Anticoagulation reversal; Direct oral anticoagulants; Warfarin; Prothrombin complex concentrate; Protamine; Idarucizumab; Andexanet alfa; Aripazine;
Keywords: ایدارویزوماب; Andexanet alfa; Ciraparantag; Direct oral anticoagulant; DOAC reversal; Emergency procedure; Factor Xa inhibitor; Idarucizumab;
Keywords: ایدارویزوماب; Idarucizumab; Andexanet alfa; DOAC; NOAC; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Antidote; Praxbind; ANNEXA-A; ANNEXA-R;
Keywords: ایدارویزوماب; Anticoagulants; Direct oral anticoagulants; Antidotes; Reversal agents; Bleeding; Hemorrhage; Adverse events; Idarucizumab;
Keywords: ایدارویزوماب; NOAC, Non vitamin K Oral Anticoagulant; VKA, Vitamin K Antagonist; ICH, IntraCranial Hemorrhage; PCC, Prothrombin Complex ConcentrateSPAF; NOACs; Reversal agents; Idarucizumab; Adexanet alfa
Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma
Keywords: ایدارویزوماب; Idarucizumab; Dabigatran; Intracranial haemorrhage; Wounds and injuries; Emergency department;
Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury
Keywords: ایدارویزوماب; Dabigatran; end-stage liver disease (ESLD); acute kidney injury (AKI); thrombin inhibitor; oral anticoagulant; renal clearance; hemorrhage; bleeding; dose adjustment; drug safety; decreased kidney function; idarucizumab;
Idarucizumab-facilitated intravenous thrombolysis in acute ischemic stroke: A therapeutic strategy requiring further investigation
Keywords: ایدارویزوماب; Hemorrhagic transformation; Idarucizumab; Thrombolysis; Dabigatran; Ischemic stroke;
Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model
Keywords: ایدارویزوماب; anticoagulants; idarucizumab; dabigatran; intraosseous; thromboelastography;
An Update on the “Novel” and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy
Keywords: ایدارویزوماب; Venous thromboembolism; Direct oral anticoagulant (DOAC); P-glycoprotein transport; CYP3A4; Idarucizumab; Thrombin time; Anti-Xa level; Andexanet-alfa;
Spontaneous Cervical Spinal Epidural Hematoma Associated with Dabigatran
Keywords: ایدارویزوماب; Anticoagulants; Idarucizumab; Spinal epidural hematoma; CT; Computed tomography; NOAC; Nonâvitamin K antagonist oral anticoagulant; SSEH; Spontaneous spinal epidural hematoma; VKA; Vitamin K antagonist;
The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation
Keywords: ایدارویزوماب; Anticoagulant; Dabigatran; Idarucizumab; Thrombin generation;
Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?
Keywords: ایدارویزوماب; bleeding; dabigatran; idarucizumab; oral anticoagulation; reversal strategies; toxicology;
Non–vitamin K antagonist oral anticoagulant reversal: hope is on the horizon
Keywords: ایدارویزوماب; Idarucizumab; Andexanet alfa; Aripazine; Ciraparantag; Anticoagulants
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
Keywords: ایدارویزوماب; Anticoagulant reversal; Dabigatran; Idarucizumab; Monoclonal antibody fragment;
Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician
Keywords: ایدارویزوماب; novel oral anticoagulants; dabigatran; rivaroxaban; edoxaban; apixaban; direct thrombin inhibitor; factor Xa; atrial fibrillation; activated charcoal; prothrombin complex concentrates; vitamin K antagonists; warfarin; recombinant factor VIIa; idarucizumab
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols
Keywords: ایدارویزوماب; Anticoagulation reversal protocols; Direct oral anticoagulants; Hospital guidelines; Idarucizumab; Life-threatening bleeding; Uncontrolled bleeding;
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects
Keywords: ایدارویزوماب; Anticoagulant reversal; Bleeding; Dabigatran; Direct oral anticoagulants; DOAC reversal; Idarucizumab;
When to stop, how to reverse, and when to restart antithrombotic drugs periendoscopically in nonvariceal upper gastrointestinal bleeding
Keywords: ایدارویزوماب; Antithrombotic; Peptic ulcer disease; UGI hemorrhage; Anticoagulant; Vitamin K antagonist (VKA); Direct oral anticoagulant (DOAC); Fresh frozen plasma (FFP); Thienopyridine; Aspirin; NSAID; Prothrombin complex concentrates (PCC); Idarucizumab;